Matrix metalloproteinase-2 and -9 involvement in canine tumors

Veterinary Pathology

Volumn 40, Issue 4, 2003, Pages 382-394

  Loukopoulos, P ^a,b   Mungall, B A ^a   Straw, R C ^a   Thornton, J R ^a   Robinson, W F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Dogs; Gelatin zymography; Gelatinases; Immunohistochemistry; Matrix metalloproteinases; Neoplasms; p53

Indexed keywords

GELATINASE A; GELATINASE B; TUMOR MARKER;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; CANCER CLASSIFICATION; CARCINOGENESIS; CONTROLLED STUDY; DOG DISEASE; ENZYME ACTIVITY; FIBROSARCOMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; OSTEOSARCOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; ZYMOGRAPHY; ANIMAL; ANIMAL DISEASE; DOG; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; DOG DISEASES; DOGS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASMS;

EID: 0141923554     PISSN: 03009858     EISSN: None     Source Type: Journal    
DOI: 10.1354/vp.40-4-382     Document Type: Article

References (73)

1. Ara T, Fukuzawa M, Kusafuka T: Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J Pediatr Surg 33:1272-1278, 1998
2. Arican M, Ceylan C: Metalloproteinases in canine experimental traumatic keratoconjunctivitis. J Vet Med A 46:527-532, 1999
3. Bergman PJ, MacEwen EG, Kurzman ID: Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 10:76-81, 1996
4. Birkedal-Hansen H: Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 64:474-484, 1993
5. Breslow NE, Day NE: I. The analysis of case-control studies. In: Statistical Methods in Cancer Research, pp. 192-210. IARC, Lyon, France, 1980
6. Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: a review of antitumour activity. Ann Oncol 6: 967-974, 1995
7. Chiarugi V, Magnelli L, Cinelli M: Oncogenes, p53, and tumor angiogenesis. J Cancer Res Clin Oncol 124:523-525, 1998
8. Clegg PD, Coughlan AR, Riggs CM: Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine Vet J 29:343-348, 1997
9. Clohisy DR, Ramnaraine ML: Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res 16:660-666, 1998
10. Collier IE, Wilhelm SM, Eisen AZ: H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 263:6579-6587, 1988
11. Coughlan AR, Carter SD, Robertson DH: Zymographic analysis of synovial fluid metalloproteinases in canine osteoarthritis. Vet Comp Orthop Traumatol 8:62, 1995
12. Coughlan AR, Robertson DHL, Bennett D: Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis. Vet Rec 143:219-223, 1998
13. Coughlan AR, Robertson DHL, Burke R: Isolation and identification of canine matrix metalloproteinase-2 (MMP-2). Vet J 155:231-237, 1998
14. Cross JC, Werb Z, Fisher SJ: Implantation and the placenta: key pieces of the development puzzle. Science 266:1508-1518, 1994
15. Dalberg K, Eriksson E, Enberg U: Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 24:334-340, 2000
16. Davies B, Waxman J, Wasan H: Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365-5369, 1993
17. Dong Y, Walsh MD, McGuckin MA: Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 74:407-415, 1997
18. Fidler IJ: Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 43(Suppl):S3-S10, 1999
19. Garzetti GG, Ciavattini A, Lucarini G: Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer 85:2219, 1999
20. Gilbert SJ, Wotton PR, Tarlton JF: Increase expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy. Cardiovasc Res 34: 377-383, 1997
21. Jung K, Lein M, Ulbrich N: Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects. Prostate 34: 130-136, 1998
22. Kawamata H, Uchida D, Hamano H: Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol 13:699-704, 1998
23. Kawano N, Osawa H, Takaaki I: Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms. Hum Pathol 28: 613-622, 1997
24. Kawashima A, Okada Y, Nakanishi I: Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. Gen Diagn Pathol 142:129-137, 1996/97
25. Kirpensteijn J, Kik M, Rutteman GR: Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol 39:240-246, 2002
26. Kleiner DE, Stetler-Stevenson WG: Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218:325-329, 1994
27. Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43(Suppl):S42-S51, 1999
28. Lana SE, Ogilvie GK, Hansen RA: Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 61:111-114, 2000
29. Leber TM, Balkwill FR: Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem 249:24-28, 1997
30. Lee JSY: The Effect of Batimastat, a Matrix Metalloproteinase Inhibitor, on Experimental Bone Metastasis in an Animal Model, pp. 1-123. University of Manitoba, Winnipeg, Manitoba, Canada, 1998
31. Leibman NF, Lana SE, Hansen RA: Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. J Vet Intern Med 14:583-586, 2000
32. Madlener M, Parks WC, Werner S: Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 242:201-210, 1998
33. Martel-Pelletier J, McCollum R, Fujimoto N: Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 70:807-815, 1994
34. Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 14:455-463, 1992
35. Matrisian LM, Hogan BL: Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development. Curr Top Dev Biol 24:219-259, 1990
36. McDonell S, Morgan M, Lynch C: Role of matrix metalloproteinases in normal and disease processes. Biotech Soc Transact 27:734-740, 1999
37. Morodomi T, Ogata Y, Sasaguri Y: Purification and characterisation of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J 285:603-611, 1992
38. Moses MA, Wiederschain D, Loughlin KR: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395-1399, 1998
39. Mungall BA, Pollitt CC: Zymographic analysis of equine laminitis. Histochem Cell Biol 112:467-472, 1999
40. Mungall BA, Pollitt CC, Collins R: Localisation of gelatinase activity in epidermal hoof lamellae by in situ zymography. Histochem Cell Biol 110:535-540, 1998
41. Ogura E, Senzaki H, Kiyozuka Y: Expression and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases as a prognostic factor in advanced colorectal carcinomas. Oncol Rep 4:701-705, 1997
42. Ohashi K, Nemoto T, Nemori R: Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 88:2201, 2000
43. Okada Y, Naka K, Kawamura K: Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 72:311-322, 1995
44. Olson MW, Toth M, Gervasi DC: High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. J Biol Chem 273:10672-10681, 1998
45. Papparella S, Restucci B, Maiolino P: Immunohistochemical distribution of type IV collagenase in normal, dysplastic and neoplastic canine mammary gland. J Comp Pathol 117:277-282, 1997
46. Peters H-D: Matrix-metalloproteinase-inhibitoren: eine weitere enttäuschte hoffnung in der krebstherapie? Onkologe 6:774-777, 2000
47. Pollitt CC: Basement membrane pathology: a feature of acute equine laminitis. Equine Vet J 28:38-46, 1996
48. Pollitt CC, Pass MA, Pollitt S: Batimastat (BB-94) inhibits matrix metalloproteinases of equine laminitis. Equine Vet J (Suppl 26):119-124, 1998
49. Reponen P, Sahlberg C, Munaut C: High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 124: 1091-1102, 1994
50. Richardson DW, Dodge GR: Molecular characteristics of equine stromelysin and the tissue inhibitor of metalloproteinase 1. Am J Vet Res 59:1557-1562, 1998
51. Russell DL, Salamonsen LA, Findlay JK: Immunization against the N-terminal peptide of the inhibin alpha 43-subunit (alpha N) disrupts tissue remodeling and the increase in matrix metalloproteinase-2 during ovulation. Endocrinology 136:3657-3664, 1995
52. Sakamoto A, Oda Y, Iwamoto Y: Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma. J Cancer Res Clin Oncol 125:541-548, 1999
53. Salamonsen LA: Matrix metalloproteinases and endometrial remodeling. Cell Biol Int 18:1139-1144, 1994
54. Sawaya R, Go Y, Kyritsis A, et al.: Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo. Biochem Biophys Res Commun 251:632-636, 1998
55. Schoedel KE, Ohori NP, Greco MA: Expression of metalloproteinases and tissue inhibitor in cartilaginous neoplasms of bone. Appl Immunohistochem 5:111-116, 1997
56. Seltzer JL, Eisen AZ, Bauer EA: Cleavage of type VII collagen by interstitial collagenase and type IV collagenase (gelatinase) derived from human skin. J Biol Chem 264:3822-3826, 1989
57. Senior RM, Griffin GL, Fliszar CJ: Human 92- and 72-kilodalton type IV collagenases and elastases. J Biol Biochem 266:7870-7875, 1991
58. Slayter MV, Boosinger TR, Pool RR: Histological Classification of Bone and Joint Tumors of Domestic Animals, vol. 1, pp. 1-50. Armed Forces Institute of Pathology, Washington, DC, 1994
59. Stearns M, Stearns ME: Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 8: 69-75, 1996
60. Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9:289-303, 1990
61. Steward WP: Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 43(Suppl): S56-S60, 1999
62. Straw RC, Powers BE, Klausner J: Canine mandibular osteosarcoma: 51 cases (1980-1992). J Am Anim Hosp Assoc 32:257-262, 1996
63. Straw RC, Withrow SJ, Powers BE: Management of canine appendicular osteosarcoma. Vet Clin North Am Small Anim Pract 20:1141-1161, 1990
64. Straw RC, Withrow SJ, Richter SL: Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 5:205-210, 1991
65. Sugiura Y, Shimada H, Seeger RC: Matrix metalloproteinase-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 58:2209-2216, 1998
66. Talvensaari-Mattila A, Paakko P, Hoyhtya M: Matrix metalloproteinase-2 immunoreactive protein. A marker of aggressiveness in breast carcinoma. Cancer 83:1153-1162, 1998
67. Vaes G: Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts. Clin Orthop 231:239-271, 1988
68. Walker RA, Wooley DE: Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma. Virchows Arch 435:574-579, 1999
69. Webb PM, Green A, Cummings MC: Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 90:1729-1734, 1998
70. Weinstein MC, Fineberg HV: Clinical Decision Analysis, pp. 84-108. WB Saunders, Philadelphia, PA, 1980
71. Welgus HG, Fliszar CJ, Seltzer JL: Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenases and 72-kDa type IV collagenase. J Biol Biochem 265:13521-13527, 1990
72. Woessner FJ: Quantification of matrix metalloproteinases in tissue samples. Method Enzymol 248:510-528, 1995
73. Yoshikawa T, Tsuburaya A, Noguchi Y: Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Cancer Lett 151:81, 2000